Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
Olema Oncology is seeking a Director, Commercial Insights and Analytics to build and lead an integrated insights capability supporting commercial strategy, launch readiness, and lifecycle planning. The role reports to the SVP, Commercial Strategy and Operations.
What they're looking for
- 10+ years of progressive responsibility in biopharmaceutical market research, insights, forecasting, competitive intelligence, commercial strategy, management consulting, or related disciplines
- Track record of successfully supporting late-stage assets, launch planning, and in-market brands
- Strong capability in patient-based commercial forecasting, scenario analysis, and market assessment
- Proven ability to integrate primary research, competitive intelligence, secondary analyses, epidemiology, and other evidence into a coherent strategic perspective
- Effective at presenting recommendations and influencing decisions with senior executives and cross-functional leadership teams
- Successful management of agencies, consultants, and other external partners
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs